Five-part SeriesClinical NeurologyPsychopharmacologyClinical NeurosciencePharmacotherapySocial SciencesMedicinal ChemistryMedical TreatmentNeurobiology Of DiseaseNonpharmacological TreatmentsNonpharmacological Treatment OptionsPart 3NeurologyPsychoactive DrugDegenerative DiseasesPharmacological AgentNeuropharmacologyNondopaminergic PharmacotherapiesDopaminePharmacologyNeurological DiseaseMovement DisordersNeurodegenerative DiseasesParkinson DiseaseNeuroscienceMedicineDrug Discovery
This installment of a five-part series reviews the role of nondopaminergic pharmacotherapies and adjunctive options-such as monoamine oxidase type B inhibitors, catechol-O-methyltransferase inhibitors, and anticholinergic agents-in managing Parkinson's disease. Nonpharmacological treatments are also explored.
79
Neurostimulation for Parkinson's Disease with Early Motor Complications
W.M. Michael Schuepbach, Jörn Rau, Karina Knudsen et al. · New England Journal of Medicine · 2013 · 1.4K citations · Full text
Pallidal versus Subthalamic Deep-Brain Stimulation for Parkinson's Disease
Kenneth A. Follett, Frances M. Weaver, Matthew Stern et al. · New England Journal of Medicine · 2010 · 1.3K citations · Full text
Vincent J.J. Odekerken, Teus van Laar, Michiel J. Staal et al. · The Lancet Neurology · 2012 · 751 citations